Mucociliary clearance in the airways.

A Wanner, M Salathé, TG O'Riordan - American journal of …, 1996 - atsjournals.org
The ventilation of the lung ranges between 1,000 and 21,000 liters per 24 hours in humans
depending on body size and physical activity. This exposes the extensive epithelial surface …

A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis

AL Quittner, KK Marciel, MA Salathe, AE O'Donnell… - Chest, 2014 - Elsevier
BACKGROUND The Quality of Life Questionnaire-Bronchiectasis (QOL-B) is the first disease-
specific, patient-reported outcome measure for patients with bronchiectasis. Content validity …

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial

G Raghu, J Behr, KK Brown, JJ Egan… - Annals of internal …, 2013 - acpjournals.org
Chinese translation This article has been corrected. The original version (PDF) is appended
to this article as a Supplement. Background: Idiopathic pulmonary fibrosis (IPF) is …

Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report

TS Blackwell, AM Tager, Z Borok, BB Moore… - American journal of …, 2014 - atsjournals.org
The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be
approximately 3 years from the time of diagnosis, underscoring the lack of effective medical …

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

G Raghu, KK Brown, HR Collard, V Cottin… - The Lancet …, 2017 - thelancet.com
Background Lysyl oxidase-like 2 (LOXL2) catalyses collagen cross-linking and is implicated
in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The aim of this study was to …

Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 …

AF Barker, AE O'Donnell, P Flume… - The lancet Respiratory …, 2014 - thelancet.com
Background The clinical benefit of inhaled antibiotics in non-cystic fibrosis bronchiectasis
has not been established in randomised controlled trials. We aimed to assess safety and …

Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a …

G Raghu, D Lynch, JD Godwin, R Webb… - The Lancet …, 2014 - thelancet.com
Background Present guidelines for the diagnosis of idiopathic pulmonary fibrosis require
histological confirmation of surgical lung biopsy samples when high-resolution CT images …

Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores

AL Quittner, AE O'Donnell, MA Salathe, SA Lewis, X Li… - Thorax, 2015 - thorax.bmj.com
Background The Quality of Life-Bronchiectasis (QOL-B), a self-administered, patient-
reported outcome measure assessing symptoms, functioning and health-related quality of …

Aerosolized antibiotics in mechanically ventilated patients: delivery and response

LB Palmer, GC Smaldone, SR Simon… - Critical care …, 1998 - journals.lww.com
Aerosolized antibiotics in mechanically ventilated patients:... : Critical Care Medicine
Aerosolized antibiotics in mechanically ventilated patients: Delivery and response : Critical Care …

Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction

G Raghu, SD Nathan, J Behr, KK Brown… - European …, 2015 - Eur Respiratory Soc
The clinical course of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) is
not known except in advanced disease. 488 subjects in a placebo-controlled study of …